NCT03114969 - Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

March 9, 2018

Study Completion Date

March 9, 2018

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Relvar ELLIPTA

ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.

DEVICE

Symbicort TURBUHALER

TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.

DEVICE

Seretide DISKUS

DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.

DEVICE

Spiriva HANDIHALER

HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.

DEVICE

BREEZHALER

BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.

DEVICE

Incruse ELLIPTA

ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.

DEVICE

Anoro ELLIPTA

ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.

Trial Locations (13)

6191JW

GSK Investigational Site, Beek

5741 CG

GSK Investigational Site, Beek en Donk

5623 EJ

GSK Investigational Site, Eindhoven

7555 DL

GSK Investigational Site, Hengelo

1624 NP

GSK Investigational Site, Hoorn

7694 AC

GSK Investigational Site, Kloosterhaar

7442 LS

GSK Investigational Site, Nijverdal

3051 GV

GSK Investigational Site, Rotterdam

7207 AE

GSK Investigational Site, Zutphen

HA6 2RN

GSK Investigational Site, Northwood

EC1M 6BQ

GSK Investigational Site, London

SW17 0QT

GSK Investigational Site, London

DA14 6LT

GSK Investigational Site, Sidcup, Kent